Skip to main content

Table 1 Baseline clinical characteristics of the study patients

From: Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

 

COPD

Number

274

Gender, female, n (%)

17 (6.2)

Age, years

72.2 ± 7.9

Smoking Index, pack-years

55.2 ± 29.7

Current smokers, n (%)

26 (9.6)

BMI, kg/m2

22.9 ± 3.1

FEV1/FVC, %

52.4 ± 12.3

% FEV1, %

63.3 ± 21.1

GOLD grade 1/2/3/4, n (%)

63/134/61/16 (23.0/48.9/22.3/5.8)

Baseline CAT score

12.2 ± 8.0

LAMA, n (%)

170 (62.0)

LABA, n (%)

136 (49.6)

ICS, n (%)

93 (33.9)

Dose of ICSa, μg/day, median

500

WBC, n

6208 ± 1566

Neutrophil, %

60.3 ± 8.9

Neutrophil, n

3797 ± 1320

Lymphocyte, %

29.2 ± 8.2

Lymphocyte, n

1770 ± 553

NLR

2.1(1.6–2.7)

Eosinophil, %

3.4 ± 2.6

Eosinophil, n

204 ± 150

  1. Data are shown as mean ± SD and median (interquartile range)
  2. COPD chronic obstructive pulmonary disease, BMI body mass index, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, % FEV 1 ratio of predicted FEV1, GOLD Global Initiative for Chronic Obstructive Lung Disease, CAT COPD assessment test, LAMA long-acting muscarinic antagonist, LABA long-acting β2 agonist, ICS inhaled corticosteroids, WBC white blood cell, NLR Neutrophil-to-Lymphocyte ratio
  3. aDose of inhaled corticosteroid is shown as fluticasone propionate equivalent